Gene expression analysis predicts insect venom anaphylaxis in indolent systemic mastocytosis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue 5, 2011, Pages 648-657

  Niedoszytko, M ^a,b   Bruinenberg, M ^b   Van Doormaal, J J ^b   De Monchy, J G R ^b   Nedoszytko, B ^a   Koppelman, G H ^b   Nawijn, M C ^b   Wijmenga, C ^b   Jassem, E ^a   Elberink, J N G Oude ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

anaphylaxis; gene expression; insect venom allergy; mastocytosis; microarray assessment; prediction of anaphylaxis

Indexed keywords

INSECT VENOM;

ADULT; ANAPHYLAXIS; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOCAL ADHESION; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; HUMAN CELL; MALE; MAST CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC MASTOCYTOSIS;

ADULT; AGED; ANAPHYLAXIS; ANIMALS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HYMENOPTERA; INSECTS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; VENOMS;

EID: 79953766409     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02521.x     Document Type: Article

References (36)

1. Valent P, Sperr W, Schwartz L, Horny H,. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3-11. (Pubitemid 39005111)
2. Akin C, Metcalfe D,. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114: 13-19. (Pubitemid 39005112)
3. Brockow K, Jofer C, Behrendt H, Ring J,. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-232.
4. Oude Elberink JN, de Monchy JG, Kors JW, van Doormaal JJ, Dubois AE,. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99: 153-154. (Pubitemid 27074911)
5. Reimers A, Müller U,. Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. Allergy Clin Immunol Int J WAO Org 2005; 17: 68-70.
6. Niedoszytko M, De Monchy J, Van Doormaal JJ, Jassem E, Oude Elberink JNG,. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64: 1237-1245.
7. Wagner N, Fritze D, Przybilla B, Hagedorn M, Rueff F,. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol 2008; 146: 162-163. (Pubitemid 351685480)
8. RuÃff F, Placzek M, Przybilla B,. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6: 284-288. (Pubitemid 44510186)
9. Simons FE, Frew AJ, Ansotegui IJ, Bochner BS, Golden DB, Finkelman FD, et al., Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120: S2-S24. (Pubitemid 46977436)
10. Jutel M, Akdis M, Blaser K, Akdis CA,. Mechanisms of allergen specific immunotherapy-T-cell tolerance and more. Allergy 2006; 61: 796-807. (Pubitemid 43893981)
11. Konno S, Hizawa N, Nishimura M, Huang SK,. Osteopontin: a potential biomarker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses. Allergol Int 2006; 55: 355-359. (Pubitemid 46065423)
12. Mueller HL,. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966; 3: 331-333.
13. Kazmierska J, Malicki J,. Application of the Naïve Bayesian Classifier to optimize treatment decisions. Radiother Oncol 2008; 86: 211-216. (Pubitemid 351215196)
14. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al., KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008; 36: 480-484.
15. Nogales-Cadenas R, Carmona-Saez P, Vazquez M, Vicente C, Yang X, Tirado F, et al., GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res 2009; 37: 317-322.
16. Liu SM, Xavier R, Good KL, Chtanova T, Newton R, Sisavanh M, et al., Immune cell transcriptome datasets reveal novel leukocyte subset-specific genes and genes associated with allergic processes. J Allergy Clin Immunol 2006; 118: 496-503. (Pubitemid 44142717)
17. Cheung J, Petek E, Nakabayashi K, Tsui LC, Vincent JB, Scherer SW,. Identification of the human cortactin-binding protein-2 gene from the autism candidate region at 7q31. Genomics 2001; 78: 7-11. (Pubitemid 33043652)
18. Patel N, Brinkman-Van der Linden ECM, Altmann SW, Gish K, Balasubramanian S, Timans JC, et al., OB-BP1/Siglec-6: a leptin- and sialic acid-binding protein of the immunoglobulin superfamily. J Biol Chem 1999; 274: 22729-22738.
19. You XJ, Bryant PJ, Jurnak F, Holcombe RF,. Expression of Wnt pathway components frizzled and disheveled in colon cancer arising in patients with inflammatory bowel disease. Oncol Rep 2007; 18: 691-694.
20. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, et al., Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2008; 27: 1478-1488. (Pubitemid 351317458)
21. Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, et al., Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol 2009; 217: 103-112.
22. van der Heul-Nieuwenhuijsen L, Dits N, Van Ijcken W, de Lange D, Jenster G,. The FOXF2 pathway in the human prostate stroma. Prostate 2009; 69: 1538-1547.
23. Kobayashi S, Ito A, Okuzaki D, Onda H, Yabuta N, Nagamori I, et al., Expression profiling of PBMC-based diagnostic gene markers isolated from vasculitis patients. DNA Res 2008; 15: 253-265.
24. Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, et al., G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 2008; 33: 397-404.
25. Dong C, Davis RJ, Flavell RA,. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72. (Pubitemid 34293420)
26. Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, et al., Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004; 18: 1964-1970. (Pubitemid 40028422)
27. Sly LM, Kalesnikoff J, Lam V, Wong D, Song C, Omeis S, et al., IgE-induced mast cell survival requires the prolonged generation of reactive oxygen species. J Immunol 2008; 181: 3850-3860.
28. RuÃff F, Przybilla B, Bilõ MB, Müller U, Scheipl F, Aberer W, et al., Predictors of severe systemic anaphylactic reactions in patients with Hymenopteravenom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124: 1047-1054.
29. Niedoszytko M, Bruinenberg M, de Monchy J, Wijmenga C, Platteel M, Jassem E, et al., Gene expression analysis in predicting the effectiveness of insect venom immunotherapy. J Allergy Clin Immunol 2010; 125: 1092-1097.
30. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, et al., Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007; 110: 2331-2333. (Pubitemid 47523152)
31. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-Lõpez MI, Vega A, et al., Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 125: 1269-1278.
32. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al., Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123: 680-686.
33. Golden DB, Marsh DG, Freidhoff LR, Kwiterovich KA, Addison B, Kagey-Sobotka A, et al., Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol 1997; 100: 760-766. (Pubitemid 28298993)
34. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, et al., Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 2009; 6: e24.
35. van t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536. (Pubitemid 34130608)
36. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al., KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372. (Pubitemid 44497521)